Psychopharmacology 2013-02-01

Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.

Maria Sabrina Spano, Liana Fattore, Francesca Cadeddu, Walter Fratta, Paola Fadda

Index: Psychopharmacology 225(3) , 531-42, (2013)

Full Text: HTML

Abstract

Chronic cannabis use can induce psychotic states that resemble schizophrenia. Yet, schizophrenic patients often smoke cannabis as a form of self-medication to counter the aversive symptoms of schizophrenia. We recently demonstrated an ameliorating effect of cannabinoid self-administration (SA) on negative and cognitive schizophrenia-like symptoms induced experimentally by the non-competitive N-methyl-D-aspartate receptor antagonist phencyclidine (PCP). Whether cannabinoid SA alleviates or exacerbates schizophrenia-like positive symptoms is still unclear.This follow-up study aimed to evaluate the effect of self-administered cannabinoid on PCP-induced schizotypic positive symptoms in adult rats.Male rats were trained to self-administer either the cannabinoid CB1 receptor agonist WIN 55,212-2 (WIN; 12.5 μg/kg/infusion) or its vehicle (Veh) intravenously. The effects of acute and chronic intermittent intraperitoneal administration of PCP (2.5 mg/kg) on motor parameters were then tested in Veh-SA and WIN-SA.Cannabinoid SA significantly attenuated the psychotomimetic effects of PCP exposure observed in control rats. Following acute PCP administration, WIN-SA animals displayed more frequent rearing and lower anxiety-like profile than Veh-SA rats. WIN-SA rats also exhibited lower behavioural sensitisation to chronic PCP treatment as demonstrated by reduced hyperlocomotion in response to an acute PCP challenge. In addition, parallel experiments performed in experimenter-administered rats that received WIN at comparable SA doses confirmed the ameliorating effects of cannabinoid exposure on PCP-induced schizotypic behaviours, indicating that motivational effects were not responsible for the ameliorative effects of cannabinoids.Our results indicate that cannabis may exert protective effects on positive schizotypic symptoms in adult animals such as hypermotility and anxiety state.


Related Compounds

  • phencyclidine
  • PHENCYCLIDIN...

Related Articles:

Ontogenetic influence on rat susceptibility to lindane seizure after pretreatment with phencyclidine.

2013-03-01

[Environ. Toxicol. Pharmacol. 35(2) , 161-70, (2013)]

Behavioral phenotypes in schizophrenic animal models with multiple combinations of genetic and environmental factors.

2013-01-01

[J. Pharmacol. Sci. 121(3) , 185-91, (2013)]

Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse.

2013-03-01

[Psychopharmacology 226(1) , 91-100, (2013)]

mGluR5 antagonist-induced psychoactive properties: MTEP drug discrimination, a pharmacologically selective non-NMDA effect with apparent lack of reinforcing properties.

2014-04-01

[J. Pharmacol. Exp. Ther. 349(1) , 155-64, (2014)]

Differential effects of subchronic phencyclidine on anxiety in the light-enhanced startle-, light/dark exploration- and open field tests.

2013-04-15

[Behav. Brain Res. 243 , 61-5, (2013)]

More Articles...